Free Trial

Organigram (OGI) to Release Quarterly Earnings on Monday

Organigram logo with Medical background

Organigram (NASDAQ:OGI - Get Free Report) is anticipated to issue its Q2 2025 quarterly earnings data before the market opens on Monday, May 12th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $61.27 million for the quarter.

Organigram (NASDAQ:OGI - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.02). Organigram had a negative net margin of 31.69% and a negative return on equity of 8.59%. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Organigram Price Performance

NASDAQ OGI traded up $0.07 on Friday, hitting $1.18. 670,453 shares of the stock were exchanged, compared to its average volume of 689,603. The business's fifty day moving average is $1.05 and its 200 day moving average is $1.37. Organigram has a 52 week low of $0.85 and a 52 week high of $2.11. The company has a market capitalization of $157.93 million, a PE ratio of -3.11 and a beta of 1.35.

About Organigram

(Get Free Report)

Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.

Read More

Earnings History for Organigram (NASDAQ:OGI)

Should You Invest $1,000 in Organigram Right Now?

Before you consider Organigram, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.

While Organigram currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines